GUGGENHIME ANDREW sold $530K of PCVX
GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at $53.00 ($0.53M total) on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides a fresh datapoint on insider activity (10,000-share open-market sale at $53) but does not introduce new company fundamentals.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of new fundamentals suggest limited trading impact.
What to watch
Insider sales can be scheduled regardless of outlook; without accompanying buys, guidance changes, or material events, the signal is usually weak.
Background
The article is an SEC Form 4 insider transaction for Vaxcyte, Inc. (PCVX) by Andrew Guggenheim (President and CFO).
Ticker impact
SEC Form 4 shows Vaxcyte CFO sold 10,000 shares at $53 on 2026-06-18 under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this filing; any reaction is likely muted.
The disclosure is a scheduled open-market sale (Code S) with a stated 10b5-1 plan, and no new operating/financial/regulatory facts are provided.
Market effects
No sector read-across; this is a single-company insider transaction with no new clinical or regulatory information.
None indicated.
None indicated.
Counterpoint
The sale may be purely liquidity/tax-driven under a pre-arranged 10b5-1 plan, so it may not reflect bearish expectations.
Key entities
- public_companyVaxcyte, Inc.
Issuer of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.
- insiderGUGGENHIME ANDREW
President and CFO who executed the reported sale.
